TY - JOUR
T1 - A molecular perspective for the development of antibodies against the human respiratory syncytial virus
AU - Loaiza, Ricardo A.
AU - Ramírez, Robinson A.
AU - Sepúlveda-Alfaro, Javiera
AU - Ramírez, Mario A.
AU - Andrade, Catalina A.
AU - Soto, Jorge A.
AU - González, Pablo A.
AU - Bueno, Susan M.
AU - Kalergis, Alexis M.
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2024/2
Y1 - 2024/2
N2 - The human respiratory syncytial virus (hRSV) is the leading etiologic agent causing respiratory infections in infants, children, older adults, and patients with comorbidities. Sixty-seven years have passed since the discovery of hRSV, and only a few successful mitigation or treatment tools have been developed against this virus. One of these is immunotherapy with monoclonal antibodies against structural proteins of the virus, such as Palivizumab, the first prophylactic approach approved by the Food and Drug Administration (FDA) of the USA. In this article, we discuss different strategies for the prevention and treatment of hRSV infection, focusing on the molecular mechanisms against each target that underly the rational design of antibodies against hRSV. At the same time, we describe the latest results regarding currently approved therapies against hRSV and the challenges associated with developing new candidates.
AB - The human respiratory syncytial virus (hRSV) is the leading etiologic agent causing respiratory infections in infants, children, older adults, and patients with comorbidities. Sixty-seven years have passed since the discovery of hRSV, and only a few successful mitigation or treatment tools have been developed against this virus. One of these is immunotherapy with monoclonal antibodies against structural proteins of the virus, such as Palivizumab, the first prophylactic approach approved by the Food and Drug Administration (FDA) of the USA. In this article, we discuss different strategies for the prevention and treatment of hRSV infection, focusing on the molecular mechanisms against each target that underly the rational design of antibodies against hRSV. At the same time, we describe the latest results regarding currently approved therapies against hRSV and the challenges associated with developing new candidates.
KW - Human respiratory syncytial virus
KW - Immunotherapy
KW - Monoclonal antibodies
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85182385235&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2023.105783
DO - 10.1016/j.antiviral.2023.105783
M3 - Review article
C2 - 38145755
AN - SCOPUS:85182385235
SN - 0166-3542
VL - 222
JO - Antiviral Research
JF - Antiviral Research
M1 - 105783
ER -